Cargando…

Rituximab, MS, and pregnancy

OBJECTIVE: To describe the safety and efficacy of rituximab (RTX) in MS and pregnancy, we conducted a retrospective cohort study of 74 pregnancies among 55 women treated with RTX for MS and their offspring. METHODS: We used prospectively collected information from the electronic health record at Kai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Jessica B., Hellwig, Kerstin, Fink, Katharina, Lyell, Deirdre J., Piehl, Fredrik, Langer-Gould, Annette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217660/ https://www.ncbi.nlm.nih.gov/pubmed/32358226 http://dx.doi.org/10.1212/NXI.0000000000000734

Ejemplares similares

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder
por: Ciplea, Andrea Ines, et al.
Publicado: (2020)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

MS, pregnancy and COVID-19
por: Yam, Charmaine, et al.
Publicado: (2020)

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)

Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2023)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Pregnancy does not modify the risk of MS in genetically susceptible women
por: Adams, Cameron J., et al.
Publicado: (2020)

Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility
por: Hellwig, Kerstin, et al.
Publicado: (2016)

Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes
por: Ciplea, Andrea Ines, et al.
Publicado: (2020)

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD
por: Das, Gitanjali, et al.
Publicado: (2018)

Environmental and genetic risk factors for MS: an integrated review
por: Waubant, Emmanuelle, et al.
Publicado: (2019)

MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics
por: Langer-Gould, Annette, et al.
Publicado: (2018)

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
por: Evertsson, Björn, et al.
Publicado: (2020)

Adverse Pregnancy Outcomes by Degree of Maternal Serum Analyte Elevation: A Retrospective Cohort Study
por: Yeaton-Massey, Amanda, et al.
Publicado: (2020)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023)

Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data
por: Rouse, Caroline E., et al.
Publicado: (2016)

Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma
por: Millet, Aurélien, et al.
Publicado: (2021)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab
por: Linden, Johan, et al.
Publicado: (2019)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy
por: Dehghanimahmoudabadi, Azin, et al.
Publicado: (2022)

Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
por: Duell, Frida, et al.
Publicado: (2020)

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial
por: Piehl, Fredrik, et al.
Publicado: (2022)

Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
por: Esmaeili, Sara, et al.
Publicado: (2021)

Rituximab induced cytokine release syndrome in an MS patient: A case report
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Preeclampsia treatment in severe acute respiratory syndrome coronavirus 2
por: Joudi, Noor, et al.
Publicado: (2020)

Relapsing and progressive MS: the sex-specific perspective
por: Rommer, Paulus Stefan, et al.
Publicado: (2020)

Editorial Response to Drs. Simone and Mancusi
por: Langer-Gould, Annette
Publicado: (2020)

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020)

No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination
por: Lamb, Favelle, et al.
Publicado: (2016)

Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level
por: Langer‐Gould, Annette, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jro4us3fhggmqqgt5h13p5bj4q